DonCorleone77
Posted - 8 hours ago
$NBIX Wells Fargo upgrades Neurocrine with pipeline 'turning a corner' Wells Fargo upgraded Neurocrine to Overweight from Equal Weight with a price target of $170, up from $140. The analyst thinks the company's pipeline is "turning a corner." The Crinecerfont launch and Neurocrine's pipeline gives investors "enough to think about beyond Ingrezza and this looks like a good long-term stock to own," the analyst tells investors in a research note. Wells says "pipeline and second acts" tend to be key for biotechnology stocks looking to make a jump from a $10B-$15B market capitalization towards becoming a large-cap. Neurocrine now has a second act in Crinecerfont which could be a $1.5B peak drug and is still underappreciated, Wells contends.
OpenOutcrier
Posted - 16 hours ago
$NBIX (+6.8% pre) Neurocrine reports promising phase 2 depression drug data - inv https://ooc.bz/l/31101
Stock_Titan
Posted - 17 hours ago
$NBIX $TAK Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-reports-positive-phase-2-data-for-nbi-1065845-3tb0f0elruir.html
insiderbuyingselling
Posted - 6 days ago
$NBIX new insider selling: 19818 shares. http://insiderbuyingselling.com/?t=NBIX
DonCorleone77
Posted - 1 week ago
$VYGR $NBIX Voyager announces selection of development candidate for GBA1 Program Voyager Therapeutics (VYGR) announced that the joint steering committee with its collaborator Neurocrine Biosciences (NBIX) has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson's disease and other GBA1-mediated diseases. The candidate combines a GBA1 gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from Voyager's TRACER capsid discovery platform. The companies expect to file an Investigational New Drug application with the FDA for the program in 2025. Selection of the development candidate triggered a $3 million milestone payment to Voyager, which the Company expects to receive in the second quarter of 2024. Voyager is eligible to receive additional future development and commercialization milestone payments based on the further advancement of this program. The GBA1 program is being developed under the 2023 strategic collaboration agreement between Voyager and Neurocrine Biosciences for research, development, manufacture, and commercialization of certain AAV gene therapy products for programs targeting Parkinson's disease and other GBA1-mediated diseases and three other undisclosed programs to address central nervous system diseases or conditions associated with rare genetic targets. Under the terms of the 2023 collaboration agreement, Voyager is eligible to receive up to $1.5 billion in potential development milestone payments, as well as additional commercial milestone payments, tiered royalties on net sales, and program funding. Voyager maintains an option to elect 50/50 cost- and profit-sharing in the U.S. for the GBA1 program following topline data from the first Parkinson's disease clinical trial.
Stock_Titan
Posted - 1 week ago
$NBIX Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-rp61jz9wo8oe.html
smartkarma
Posted - 2 weeks ago
$NBIX | Neurocrine Biosciences Inc.: Initiation Of Coverage - Continued Investment & Growth for INGREZZA Paving The Way Forward? - Major Drivers
"Neurocrine Biosciences Inc, a biopharmaceutical company specializing in neurologic, psychiatric, and endocrine related disorders, showed..." - Baptista Research (Baptista Research)
Key Points:Neurocrine Biosciences Inc, a biopharmaceutical company specializing in neurologic, psychiatric, and endocrine related disorders, showed significant growth during its remarkable year of 2023.According to Neurocrine's executives, the firm's performance reflected the ongoing progress and the successful execution of business strategies with nearly 30% year-over-year sales growth for its flagship product, INGREZZA, which is a drug indicated for the treatment of tardive dyskinesia in...
Read more: https://www.smartkarma.com/insights/neurocrine-biosciences-inc-initiation-of-coverage-continued-investment-growth-for-ingrezza-paving-the-way-forward-major-drivers
Stock_Titan
Posted - 2 weeks ago
$NBIX Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-announces-first-patient-dosed-in-phase-2-obvggr1pub37.html
trendx
Posted - 3 weeks ago
$NBIX has flushed out traders on both the sides, and is ready to blast upwards.
Stock_Titan
Posted - 03/28/24
$NBIX Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-l9k90ykea7de.html
AskLou
Posted - 03/27/24
$NBIX if you got stopped into the failed breakout last week and then jettisoned on the sell stop following O’Neil rules, don’t fret. This is an indication liquidity is leaving the market. Stay tuned as often it is the second mouse that gets the cheese.
Monkey_Banana_Genius
Posted - 03/27/24
$NBIX false breakout but like it at $130 level
michael23
Posted - 03/27/24
$NBIX Added yesterday and today
OMW2Money
Posted - 03/25/24
$NBIX 👀👀
basscat12
Posted - 03/25/24
$NBIX $V $UBER Money Monday dawning with another week of opportunities! Are you prepared? Coffee on th the fire; saddle up, let's ride!
Nosh
Posted - 1 month ago
$DDS $BECN $AU $NBIX Buy set 1 in order of size. Everything is a starter except AU which I am playing in and out of for a few months now.
AskLou
Posted - 1 month ago
$NBIX looks like a classic O'Neil breakout. Long
fastmoneytraderz
Posted - 1 month ago
shorted $NBIX 147.38 covered 144.92
AnchorsAweigh
Posted - 1 month ago
$NBIX huge breakout
FannyPackin
Posted - 1 month ago
$NBIX didn’t even get to 129, got bought up quick.. just the way she goes, 👀 ing good…
greenype
Posted - 1 month ago
$SPRB meanwhile, at $NBIX headquarters...
wealthwithstocks
Posted - 1 month ago
$NBIX Close to new high on great fundamentals. https://app.ziggma.com/securities/NBIX
insiderbuyingselling
Posted - 1 month ago
$NBIX new insider selling: 1800 shares. http://insiderbuyingselling.com/?t=NBIX
MarketSurge
Posted - 1 month ago
Neurocrine Biosciences $NBIX is approaching a buy point after shares of the drug developer retook the 50-day moving average.
Stock_Titan
Posted - 1 month ago
$NBIX Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-to-participate-at-virtual-investor-noetosszepu2.html
1986iamwallstreet
Posted - 1 month ago
$NBIX let’s go 140 the highs
1986iamwallstreet
Posted - 1 month ago
$NBIX ripping 🚀🚀🚀
DailyStocksPicks
Posted - 1 month ago
The Direxion Daily S&P Biotech Bear 3X Shares ($LABD), known for its aim to deliver three times the inverse exposure to the S&P Biotechnology Select Industry Index, may be considered oversold due to bullish trends in the biotechnology sector. Groundbreaking innovations, significant venture capital inflows, and the doubling of deal values have fueled optimism, drawing substantial investment into biotech. Regulatory advancements and the sector's resilience amidst economic downturns further enhance its appeal, contributing to a positive outlook. However, this optimism for biotech can exert downward pressure on LABD's price, as its performance is inversely related to the sector's success, highlighting the complex dynamics at play between sectoral developments and the valuation of leveraged inverse ETFs $VRTX $NBIX $ALKS $HARP For more details https://youtu.be/QDW75yHzRo0
Thelonius_Stonk
Posted - 1 month ago
$NBIX monthly looks like a tweezer top, would love to get some ~115-120
